Article: Results of Multinational Trial Investigating Pegasys(R) and Copegus(R) in Patients with Hepatitis C and HIV Announced.

NUTLEY, N.J., Feb. 7 /PRNewswire/ -- Roche today announced the results of a multinational trial designed to evaluate the safety and efficacy of Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) compared with conventional interferon alfa-2a/ribavirin for the treatment of chronic hepatitis C in patients co-infected with HIV, will be presented at a conference beginning Sunday, February 8.

The results of the trial showed that a combination of Pegasys and Copegus produced significantly higher sustained virological response rates than conventional interferon and ribavirin in HCV/HIV co-infection (40% vs. 12%, P

A release with the full study results will be ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!